Log in to save to my catalogue

Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhi...

Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhi...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7788060

Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement

About this item

Full title

Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement

Publisher

England: BMJ Publishing Group Ltd and European League Against Rheumatism

Journal title

Annals of the rheumatic diseases, 2021-01, Vol.80 (1), p.71-87

Language

English

Formats

Publication information

Publisher

England: BMJ Publishing Group Ltd and European League Against Rheumatism

More information

Scope and Contents

Contents

ObjectivesJanus kinase inhibitors (JAKi) have been approved for use in various immune-mediated inflammatory diseases. With five agents licensed, it was timely to summarise the current understanding of JAKi use based on a systematic literature review (SLR) on efficacy and safety.MethodsExisting data were evaluated by a steering committee and subsequ...

Alternative Titles

Full title

Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7788060

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7788060

Other Identifiers

ISSN

0003-4967

E-ISSN

1468-2060

DOI

10.1136/annrheumdis-2020-218398

How to access this item